Division of Vascular Surgery and Endovascular Therapies, Emory University School of Medicine, Atlanta, Ga.
Division of Vascular Surgery and Endovascular Therapies, Emory University School of Medicine, Atlanta, Ga.
J Vasc Surg. 2020 Feb;71(2):701-711. doi: 10.1016/j.jvs.2019.05.027. Epub 2019 Jul 18.
Abnormalities in glucose metabolism are common in patients with arterial disease. Chronic hyperglycemia and insulin resistance contribute to the complexity of vascular disorders. They also overlap with the effects of perioperative hyperglycemia on adverse perioperative outcomes. We provide an overview of the pathophysiologic consequences of dysglycemia and the evidence behind glycemic control in patients undergoing vascular surgery.
We searched the literature for major studies evaluating the pathophysiology of hyperglycemia in microvascular and macrovascular beds, randomized trials in perioperative populations, and meta-analyses. The literature was summarized to guide therapy in the population of vascular patients and for the perioperative period.
National standards for glycemic control after vascular interventions were not identified. Mounting evidence exists for the long-term consequences of poor glycemic control on the progression of vascular disease. Similarly, there is a large body of evidence supporting tight control of hyperglycemia after general and cardiac surgery during the critical perioperative period. The absolute glucose target remains controversial. Randomized controlled studies are lacking in vascular surgery patients, but the current evidence can be extrapolated to guide management after vascular interventions. Glycated hemoglobin is a biomarker for increased mortality and vascular morbidity after vascular surgery.
Hyperglycemia contributes to poor outcome in the vascular patient. Further vascular focused studies are required to determine the proper perioperative serum glucose target and the long-term glycated hemoglobin range.
动脉疾病患者的糖代谢异常很常见。慢性高血糖和胰岛素抵抗导致血管疾病复杂化。它们还与围手术期高血糖对不良围手术期结局的影响重叠。我们提供了一篇关于糖代谢异常的病理生理后果以及血管外科患者血糖控制证据的综述。
我们搜索了评估微血管和大血管床高血糖病理生理学、围手术期人群随机试验和荟萃分析的主要研究文献。对文献进行了总结,以指导血管患者人群和围手术期的治疗。
未确定血管介入后血糖控制的国家标准。越来越多的证据表明,血糖控制不佳对血管疾病进展的长期后果。同样,也有大量证据支持在一般和心脏手术后的关键围手术期严格控制高血糖。绝对血糖目标仍存在争议。血管外科患者缺乏随机对照研究,但现有证据可以外推以指导血管介入后的管理。糖化血红蛋白是血管手术后死亡率和血管发病率增加的生物标志物。
高血糖会导致血管患者预后不良。需要进一步进行血管重点研究,以确定适当的围手术期血清葡萄糖目标和长期糖化血红蛋白范围。